Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis [3]

Journal of the National Cancer Institute

Volumn 98, Issue 8, 2006, Pages 562-563

  Gonçalves, Anthony ^a,g   Monges, Genevieve ^a,b,g   Yang, Ying ^a,d   Palmerini, Fabienne ^a,d   Dubreuil, Patrice ^a,d   Noguchi, Tetsuro ^b,c   Jacquemier, Jocelyne ^b   Di Stefano, Donatella ^e   Delpero, Jean Robert ^a,f,g   Sobol, Hagay ^a,c,g   Bertucci, Francois ^a,g  

^a INSTITUT PAOLI CALMETTES   (France)

^b Département de BioPathologie   (France)

^c opital d'Enfants de la Timone AP HM   (France)

^d INSERM   (France)

^e Dépt d'Oncol Méd   (France)

^f L'Institut Paoli Calmette   (France)

^g AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GONADORELIN ANTAGONIST; IMATINIB; LEUCINE; METHIONINE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROGESTERONE RECEPTOR; STEM CELL FACTOR RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; TUMOR MARKER;

ADULT; AMINO ACID SUBSTITUTION; ANTIGEN EXPRESSION; CANCER GROWTH; CANCER RECURRENCE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DNA SEQUENCE; DOSE RESPONSE; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; FIBROMATOSIS; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HETEROZYGOSITY; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; MUTATIONAL ANALYSIS; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CHEMISTRY; DRUG ANTAGONISM; FIBROMA; GENETICS; MUTATION;

ADULT; ANTINEOPLASTIC AGENTS; FEMALE; FIBROMA; GERM-LINE MUTATION; HUMANS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; TUMOR MARKERS, BIOLOGICAL;

EID: 33646450955     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj137     Document Type: Letter

References (7)

1. Ballo MT, Zagars GK, Pollack A, Pisters PW, Pollack RA. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol 1999;17:158-67.
2. Janinis J, Patriki M, Vini L, Aravantinos G, Whelan JS. The pharmacological treatment of aggressive fibromatosis: A systematic review. Ann Oncol 2003;14:181-90.
3. Gega M, Yanagi H, Yoshikawa R, Noda M, Ikeuchi H, Tsukamoto K, et al. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol 2006;24:102-5.
4. Mace J, Sybil Biermann J, Sondak V, McGinn C, Hayes C, Thomas D, et al. Response of extra-abdominal desmoid tumors to therapy with imatinib mesylate. Cancer 2002;95:2373-9.
5. Nagata H, Worobec AS, Metcalfe DD. Identification of a polymorphism in the transmembrane domain of the protooncogene c-kit in healthy subjects. Exp Clin Immunogenet 1996;13:210-4.
6. Inokuchi K, Yamaguchi H, Tarusawa M, Futaki M, Hanawa H, Tanosaki S, et al. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia - potential clinical significance. Leukemia 2002;16:170-7.
7. Tayal S, Classen E, Bemis L, Robinson WA. C-kit expression in dedifferentiated and well-differentiated liposarcomas; immunohistochemistry and genetic analysis. Anticancer Res 2005;25:2215-20.